Hi Everyone
The Immunogenicity Discussion Group is looking forward to hosting Devangi Mehta and colleagues on Wednesday, June 3rd (12–1pm Eastern US, 6-7pm EU) to discuss the recently published paper:
"Rethinking immunogenicity: an integrated approach reveals the PK/PD impact of pre-existing and drug-sustaining ADA"
The presentation will explore how integrated ADA, PK, and PD analyses can provide deeper insight into clinically meaningful immunogenicity than traditional tiered approaches alone, including the impact of pre-existing and drug-sustaining ADA responses on drug exposure and pharmacology.
If you would like to join the discussion, connection details are below (and attached as a calendar invite)
Looking forward to what should be a great discussion with the community.
Rob & Todd
---
________________________________________________________________________________
Microsoft Teams meeting
Join: https://teams.microsoft.com/meet/29478979084349?p=xfQhePEMtJeHbtRxsH
Meeting ID: 294 789 790 843 49
Passcode: Ar29fU9k
Need help? | System reference
Dial in by phone
+1 910-745-0533,,925590706# United States, Fayetteville
Find a local number
Phone conference ID: 925 590 706#
For organizers: 19_meeting_YmM2NWZkYjgtYzE5YS00MGI4LWI5ZmUtYzYxYWQzMDNiYzE4@thread.v2&messageId=0&language=en-US" target="_blank" rel="noopener">Meeting options | Reset dial-in PIN
________________________________________________________________________________
------------------------------
Robert Nelson
Scientific Officer, Executive Director
BioAgilytix Laboratories
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer or other entities to which I am affiliated.
------------------------------